Ivabradine hydrochloride 是一种有效且具有口服活性的HCN (超极化激活的环核苷酸门控) 通道阻滞剂,可抑制心脏起搏器电流 (If)。Ivabradine hydrochloride 以剂量依赖性降低心率而不改变血压。Ivabradine hydrochloride 具有抗惊厥、抗缺血和抗心绞痛活性。
生物活性 | Ivabradine hydrochloride is a potent and orally activeHCN (hyperpolarization-activated cyclic nucleotide-gated) channelblocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity[1][2][3][4]. |
体内研究 (In Vivo) | Ivabradine hydrochloride (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice[3]. Ivabradine hydrochloride (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities[4].
Animal Model: | 25-30 g, 6 weeks male Swiss mice[3] | Dosage: | 1, 10, 20 mg/kg | Administration: | I.p.; for 3 days | Result: | Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in all
brain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively. |
Animal Model: | 3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR[4] | Dosage: | 5, 10, 20 mg/kg | Administration: | P.o; daily for 1 weeks | Result: | Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 50 mg/mL(99.00 mM;Need ultrasonic) DMSO : 25 mg/mL(49.50 mM;Need ultrasonic) 配制储备液 1 mM | 1.9800 mL | 9.9000 mL | 19.8000 mL | 5 mM | 0.3960 mL | 1.9800 mL | 3.9600 mL | 10 mM | 0.1980 mL | 0.9900 mL | 1.9800 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 50 mg/mL (99.00 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|